



ACURATE *neo*[™]

Aortic Valve System

Length of Stay with ACURATE *neo* vs. Evolut[™] R

Routine use of the ACURATE *neo* self-expanding valve is associated with improved procedural outcomes and reduced post-operative length of stay: Insights from a single-center registry (ACURATE *neo* vs. Evolut R)

Kotronias RA, Banning AP, Kharbanda RK. Oxford University Hospital. Presented at EuroPCR 2019 by R. A. Kotronias.

Study Design

Single-center study from Oxford, Great Britain, evaluating the impact of valve selection on procedural outcomes, length of stay (LoS), and 30-day mortality in 231 patients treated with either ACURATE *neo* (n = 143) or Evolut R (n = 88) between March 2017 and September 2018.


Clinical Highlights

ACURATE *neo* demonstrates reduced post-operative complications and permanent pacemaker rates and comparable mortality and stroke rates vs. Evolut R

Improvements in procedural outcomes with ACURATE *neo* are associated with reductions in post-operative length of stay

A multivariate linear regression model identified peri-procedural complications, pre-existing RBBB, and new permanent pacemaker implantation as independent predictors of post-operative length of stay.

Procedural Outcomes



Post-Operative Length of Stay

